Skip to content

Clinical efficacy of doripenem(3g daily)against patients with obstructive pyelonephritis caused by ureteral calculi.

Clinical efficacy of doripenem(3g daily)against patients with obstructive pyelonephritis caused by ureteral calculi. - Clinical efficacy of doripenem(3g daily)against patients with obstructive pyelonephritis caused by ureteral calculi.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000010192
Enrollment
50
Registered
2013-03-10
Start date
2013-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive pyelonephritis caused by ureteral calculi.

Interventions

Doripenem 3g daily

Sponsors

Jikei university katsushika medical center,Department of urology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)2)age:20 years old or older.male and female. 3)hospitalized patients. 4)Obstructive urinary tract due to urolithiasis. 5,6)Patients showing clinical symptoms such as high fever ,miction pain,back pain,etc. 7)pyuria:white blood cells five/hpf or more in urinary sediment. 8)bacteriuria:104 CFU/mL in catheterized urine or105 CFU/mL in midstream urine.

Exclusion criteria

Exclusion criteria: 1)patient wiht prostatitis or epididymitis. 2)patient with urinary diversion. 3)patient was administered other antimicrobials and their symptom has been improved before starting administration of doripenem. 4)patient with severe underlying disease or complications, who cannot be evaluated efficacy and safety of doripenem. 5)patient with carbapenem allergies. 6)patient with severe cardiac or hepatic dysfunction. 7)patient with moderate renal dysfunction (criteria:serum creatinine>=2mg/dL) 8)patient with convulsive disorders such as epilepsy. 9)Pregnant women or females with childbearing potential. 10)patient disqualified as target by doctor. 11)Doripenem resistant pathogen has been already isolated.

Design outcomes

Primary

MeasureTime frame
Period from initiation of therapy to alleviation of fever.

Countries

Japan

Contacts

Public Contactshinichiro kira

Jikei university katsushika medical center Department of urology

kirasin1031@yahoo.co.jp0336032111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026